Loading clinical trials...
Loading clinical trials...
One-third to one-half of patients with AML relapse and in general relapsed AML patients have a poor prognosis. The treatment of relapsed AML consists of induction chemotherapy followed by Allogenic St...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
All India Institute of Medical Sciences
NCT04716452 · Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Refractory, and more
NCT06459024 · Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
NCT05190471 · Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
NCT06532084 · Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes, and more
NCT05546580 · Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions